2. Search Result
Search Result
Results for "

NNRT

" in MedChemExpress (MCE) Product Catalog:

23

Inhibitors & Agonists

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-109056
    Elsulfavirine
    2 Publications Verification

    R-1206

    		 Drug Intermediate HIV Reverse Transcriptase Carbonic Anhydrase Infection Cancer
    Elsulfavirine (R-1206) is an orally active human carbonic anhydrase (carbonic anhydrase, CA) inhibitor and an allosteric inhibitor of HIV-1 non-nucleoside reverse transcriptase (NNRT). Elsulfavirine also targets and blocks the interaction between adenylosuccinate lyase (ADSL) and insulin-induced gene proteins INSIG1/2, blocks SREBP-1-mediated de novo lipid synthesis, and inhibits the proliferation of liver cancer cells. The combination of Elsulfavirine and Lenvatinib (HY-10981) produces a synergistic anti-tumor effect. Elsulfavirine is converted into the active metabolite VM1500A in vivo, blocks the DNA polymerase activity of reverse transcriptase, and inhibits HIV-1 replication. Elsulfavirine exhibits a Ki of 1960 nM-52400 nM against human carbonic anhydrase isoforms including I, VII, VI, VA, VB, IX, XIII, XIV. Elsulfavirine is used in studies related to HIV-1 infection and liver cancer .
    Elsulfavirine
  • HY-106958
    Talviraline

    HBY 097

    		 HIV Reverse Transcriptase Infection
    Talviraline is a non-nucleoside reverse transcriptase (NNRT) inhibitor that is primarily used to inhibit the replication of human immunodeficiency virus type 1 (HIV-1). Talviraline inhibits the viral replication process by binding to a specific site of HIV-1 reverse transcriptase (RT). Talviraline can be used to study the potential countermeasures and safety of HIV-1 infection .
    Talviraline
  • HY-178341
    NNRT-IN-13

    		Reverse Transcriptase HIV Infection
    NNRT-IN-13 is a potent non-nucleoside reverse transcriptase (NNRT) inhibitor that directly inhibiting HIV-1 reverse transcriptase (IC₅₀ = 0.25 μM). NNRT-IN-13 exhibits excellent antiviral activity against wild-type HIV-1 (EC₅₀ = 0.0046 μM) and a broad spectrum of drug-resistant mutants. NNRT-IN-13 exhibits favorable in vivo metabolic and safety profiles. NNRT-IN-13 can be used for human immunodeficiency virus (HIV) research .
    NNRT-IN-13
  • HY-174303
    NNRT-IN-9

    		HIV Reverse Transcriptase Infection
    NNRT-IN-9 (Compound EG28) is a non-nucleoside reverse transcriptase (NNRT) inhibitor. NNRT-IN-9 has potent antiviral and anti-resistance activity against wild-type (WT) HIV-1 and various clinically relevant mutations (E138K and K103N + Y181C) with EC50s of 55, 67 and 3910 nM, respectively. NNRT-IN-9 can be used for acquired immune deficiency syndrome (AIDS) research .
    NNRT-IN-9
  • HY-178923
    NNRT-IN-14

    		HIV Reverse Transcriptase Infection
    NNRT-IN-14 is an HIV-1 reverse transcriptase inhibitor (IC50 = 0.175 µM). NNRT-IN-14 can form hydrogen bonds with LYS101, PRO225, and PHE227, and π–π stacking with TYR181 and TRP229. NNRT-IN-14 can be used for the study of HIV .
    NNRT-IN-14
  • HY-175667
    NNRT-IN-12

    		HIV Reverse Transcriptase Infection
    NNRT-IN-12 (compound 19) is a potent non-nucleoside reverse transcriptase (NNRT) inhibitor with an IC50 value of 0.107 μM for WT HIV-1 RT. NNRT-IN-12 shows anti-HIV-1 activity with EC50 value of 14.1, 5.03, 7.64, 27.1 nM for L100I, K103N, Y181C, Y188L mutant HIV-1 strains, respectively. NNRT-IN-12 shows cytotoxicity .
    NNRT-IN-12
  • HY-163110
    NNRT-IN-2

    		HIV Reverse Transcriptase Infection
    NNRT-IN-2 (compound 7w) is an orally available non-nucleoside reverse transcriptase inhibitor (NNRTI) with broad inhibitory effects on wild-type HIV-1 and mutant strains. NNRT-IN-2 inhibits HIV-1 reverse transcriptase with an EC50 of 22 nM. NNRT-IN-2 is insensitive to CYP and hERG and has good safety and pharmacokinetic characteristics .
    NNRT-IN-2
  • HY-174417
    NNRT-IN-10

    		Reverse Transcriptase HIV Potassium Channel Cytochrome P450 Infection
    NNRT-IN-10 is a potent, selective and orally active non-nucleoside HIV-1 reverse transcriptase (NNRTI) inhibitor with with an EC50 values ranging from 1.16 to 18.3 nM for HIV and its mutant strains. NNRT-IN-10 exhibits good pharmacokinetic properties and favorable safety profiles. NNRT-IN-10 can be used for the study of AIDS, caused by HIV-1 .
    NNRT-IN-10
  • HY-148248
    BI-2540

    		HIV Infection
    BI-2540, a chemical probe, is a HIV non-nucleoside reverse transcriptase (NNRT) inhibitor .
    BI-2540
  • HY-149928
    NNRT-IN-1

    		HIV Infection
    NNRT-IN-1 (compound 8r) is a potent non-nucleoside reverse transcriptase (NNRT) inhibitor featuring significantly anti-resistance efficacy. NNRT-IN-1 inhibits the wild-type HIV-1 and five mutant strains with EC50s in the nanomolar range. NNRT-IN-1 displays favorable pharmacokinetic properties .
    NNRT-IN-1
  • HY-19378
    MIV-150

    PC 815

    		 HIV Infection
    MIV-150 is a nonnucleoside reverse transcriptase (NNRT) inhibitor, blocking HIV-1 and HIV-2 infections, with an EC50<1 nM against HIV-1/HIV-2MN.
    MIV-150
  • HY-162720
    NNRT-IN-4

    		HIV Potassium Channel Reverse Transcriptase Infection
    NNRT-IN-4 (Compound 10p) is an inhibitor for non-nucleoside reverse transcriptase (NNRT) with an IC50 of 0.713 µM for HIV-1 RT. NNRT-IN-4 exhibits antiviral efficacy, inhibits HIV-1 wildtype and mutant strains with EC50 of 6-63 nM. NNRT-IN-4 exhibits a slight inhibitory activities against hERG (IC50=25.9 µM) and CYP enzymes (IC50>50 µM). NNRT-IN-4 exhibits good tolerability and safety in mice (2 g/kg) .
    NNRT-IN-4
  • HY-172408
    NNRT-IN-6

    		Reverse Transcriptase HIV Infection
    NNRT-IN-6 (Compound 13a) is the non-nucleoside reverse transcriptase inhibitor (NNRT) for HIV-1 reverse transcriptase (HIV-1 RT) with IC50 of 0.41 μM. NNRT-IN-6 inhibits HIV-1 wildtype and mutant strains L100I, K103N, Y181C, Y188L, E138K, F227L/V106A and RES056 with EC50 of 6.2-250 nM .
    NNRT-IN-6
  • HY-169207
    NNRT-IN-5

    		Reverse Transcriptase Cancer
    NNRT-IN-5 (compund 10d) is an orally available non-nucleoside reverse transcriptase inhibitor .
    NNRT-IN-5
  • HY-149338
    NNRT-IN-3

    		HIV Protease Infection
    NNRT-IN-3 (compound 8) is an HIV-1 non-nucleoside reverse transcriptase inhibitor (EC50=0.01 μM) .
    NNRT-IN-3
  • HY-172996
    NNRT-IN-8

    		HIV Reverse Transcriptase Infection
    NNRT-IN-8 (compound 9K) is a potent non-nucleoside reverse transcriptase inhibitor with EC50 values of 0.0014, 0.0041, 0.0077 µM for WT HIV-1, K103N, E138K, respectively .
    NNRT-IN-8
  • HY-175519
    NNRT-IN-11

    		HIV Infection
    NNRT-IN-11 (14l) is a potent non-nucleoside reverse transcriptase (NNRT) inhibitor with EC50 values of 6.50 to 52.9 nM against WT and a panel of HIV-1 mutants. NNRT-IN-11 has antiviral activity .
    NNRT-IN-11
  • HY-152233
    Reverse transcriptase-IN-4

    		HIV Infection
    Reverse transcriptase-IN-4 (compound F10) is a potent and selective non-nucleoside reverse transcriptase (NNRT) inhibitor with an EC50 value of 0.053 μM for wild-type HIV-1 and an EC50 value of 0.26 μM for HIV-1 mutant E138K . Reverse transcriptase-IN-4 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    Reverse transcriptase-IN-4
  • HY-105097
    Atevirdine mesylate

    U 87201E mesylate

    		 HIV Reverse Transcriptase Inflammation/Immunology
    Atevirdine (U 87201E) mesylate is a nonnucleoside reverse transcriptase (NNRT) inhibitor. Atevirdine mesylate can inhibit human immunodeficiency virus type 1 (HIV-1) with an IC50 of 0.06-1.6 μM. Atevirdine mesylate shows highly synergistic effects against Zidovudine/Didanosine-resistant clinical isolates of HIV-1 companied with Zidovudine (HY-17413)/Didanosine (Hy-B0249). Atevirdine mesylate can be used for the research of AIDS .
    Atevirdine mesylate
  • HY-181034
    NNRT-IN-15

    		Reverse Transcriptase HIV Infection
    NNRT-IN-15 (Compound 16a) is a potent non-nucleoside reverse transcriptase (NNRT) inhibitor. NNRT-IN-15 shows an EC50 of 3 nM for WT HIV-1 and inhibits seven mutant strains (L100I, K103N, Y181C, etc.) (EC50 = 8.2-43.4 nM). NNRT-IN-15 has low cytotoxicity against MT-4 cells (CC50 = 196.46 μM). NNRT-IN-15 also inhibit WTHIV-1RT and hERG with IC50 values of 0.7599 μM and 27.455 μM. NNRT-IN-15 can be used for research of HIV-1 infection .
    NNRT-IN-15
  • HY-182916
    NNRT-IN-16

    		HIV Reverse Transcriptase Infection
    NNRT-IN-16, Rilpivirin (HY-10574) analogue, is a non-nucleoside reverse transcriptase inhibitor (NNRTI). NNRT-IN-16 inhibits recombinant WT HIV-1 RT with an IC50 of 0.07 μM. NNRT-IN-16 exerts antiviral activity against wild-type and drug-resistant HIV-1 mutants, shows attenuated CYP isoenzyme and hERG inhibition, reduced cytotoxicity, and improved metabolic stability in human liver microsomes. NNRT-IN-16 can be used for the research of HIV-1 infection .
    NNRT-IN-16
  • HY-109056A
    Elsulfavirine sodium

    R-1206 sodium

    		 HIV Drug Intermediate Reverse Transcriptase Carbonic Anhydrase Infection Cancer
    Elsulfavirine sodium (R-1206) is an orally active human carbonic anhydrase (carbonic anhydrase, CA) inhibitor and an allosteric inhibitor of HIV-1 non-nucleoside reverse transcriptase (NNRT). Elsulfavirine sodium also targets and blocks the interaction between adenylosuccinate lyase (ADSL) and insulin-induced gene proteins INSIG1/2, blocks SREBP-1-mediated de novo lipid synthesis, and inhibits the proliferation of liver cancer cells. The combination of Elsulfavirine sodium and Lenvatinib (HY-10981) produces a synergistic anti-tumor effect. Elsulfavirine sodium is converted into the active metabolite VM1500A in vivo, blocks the DNA polymerase activity of reverse transcriptase, and inhibits HIV-1 replication. Elsulfavirine sodium exhibits a Ki of 1960 nM-52400 nM against human carbonic anhydrase isoforms including I, VII, VI, VA, VB, IX, XIII, XIV. Elsulfavirine sodium is used in studies related to HIV-1 infection and liver cancer .
    Elsulfavirine sodium
  • HY-109056R
    Elsulfavirine (Standard)

    R-1206 (Standard)

    		 Reference Standards Drug Intermediate HIV Reverse Transcriptase Carbonic Anhydrase Infection Cancer
    Elsulfavirine (Standard) is the analytical standard of Elsulfavirine (HY-109056). This product is intended for research and analytical applications. Elsulfavirine (R-1206) is an orally active human carbonic anhydrase (carbonic anhydrase, CA) inhibitor and an allosteric inhibitor of HIV-1 non-nucleoside reverse transcriptase (NNRT). Elsulfavirine also targets and blocks the interaction between adenylosuccinate lyase (ADSL) and insulin-induced gene proteins INSIG1/2, blocks SREBP-1-mediated de novo lipid synthesis, and inhibits the proliferation of liver cancer cells. The combination of Elsulfavirine and Lenvatinib (HY-10981) produces a synergistic anti-tumor effect. Elsulfavirine is converted into the active metabolite VM1500A in vivo, blocks the DNA polymerase activity of reverse transcriptase, and inhibits HIV-1 replication. Elsulfavirine exhibits a Ki of 1960 nM-52400 nM against human carbonic anhydrase isoforms including I, VII, VI, VA, VB, IX, XIII, XIV. Elsulfavirine is used in studies related to HIV-1 infection and liver cancer .
    Elsulfavirine (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: